Literature DB >> 2784266

Gadolinium-DTPA-enhanced MR imaging of the postoperative lumbar spine: time course and mechanism of enhancement.

J S Ross1, R Delamarter, M G Hueftle, T J Masaryk, M Aikawa, J Carter, C VanDyke, M T Modic.   

Abstract

To define the time course and mechanism of enhancement of epidural fibrosis after gadolinium-DTPA (Gd-DTPA) injection, we undertook a three-part study in humans and dogs with epidural scar after spine surgery. First, the dynamic in vivo contrast-enhancing properties of epidural scar were assessed by using sequential fast (18-sec) spin-echo sequences after contrast injection. Epidural scar in dogs rapidly enhanced; peak enhancement (101%) was 6 min after injection, with a slower decline toward baseline to 45% after 44 min. Epidural fibrosis in patients followed a similar pattern, with a maximum enhancement of 73% after 5 min. Paraspinal muscle had a lower peak enhancement in both patients (36%) and dogs (22%). Second, vascular injection in two dogs with India ink demonstrated multiple small vessels throughout the epidural scar. Third, light and electron microscopy was performed on epidural scar obtained at reoperation in both patients and dogs. Light microscopy showed multiple small capillaries scattered throughout a background of collagen. Electron microscopy demonstrated a wide variation in the junctions between endothelial cells ranging from "tight" to "loose." Regions of endothelial discontinuity were also visualized. This study suggests that Gd-DTPA diffuses rapidly into the extravascular space in epidural scar, with a slower, net movement toward the intravascular compartment as the agent is renally filtered. The contrast agent transgresses the endothelium through "leaky" intercellular junctions and areas of endothelial discontinuity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784266     DOI: 10.2214/ajr.152.4.825

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  15 in total

1.  MAGNETIC RESONANCE IMAGING IN FAILED BACK SURGERY SYNDROME.

Authors:  K K Sen; Amarjit Singh
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 2.  Imaging of lumbar degenerative disk disease: history and current state.

Authors:  Todd M Emch; Michael T Modic
Journal:  Skeletal Radiol       Date:  2011-08-17       Impact factor: 2.199

3.  Contrast enhanced computed tomography and magnetic resonance imaging in the diagnosis of recurrent disc herniation.

Authors:  M J Albeck; A Wagner; L L Knudsen
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

4.  MRI findings of treated bacterial septic arthritis.

Authors:  Guillaume Bierry; Ambrose J Huang; Connie Y Chang; Martin Torriani; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2012-03-20       Impact factor: 2.199

Review 5.  Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.

Authors:  Julie C Dutoit; Koenraad L Verstraete
Journal:  Skeletal Radiol       Date:  2017-03-13       Impact factor: 2.199

6.  Fat-suppression contrast-enhanced MRI in the failed back surgery syndrome: a prospective study.

Authors:  B A Georgy; J R Hesselink; M S Middleton
Journal:  Neuroradiology       Date:  1995-01       Impact factor: 2.804

7.  Contrast-enhanced MRI versus myelography and contrast-enhanced CT in postdiskectomy problems.

Authors:  M Annertz; G Hägglund; S Holtås; B Jönsson; B Strömqvist
Journal:  Eur Spine J       Date:  1992-09       Impact factor: 3.134

8.  NEED FOR PRECISE PROTOCOL IN MAGNETIC RESONANCE IMAGING OF THE POST OPERATIVE SPINE.

Authors:  K K Sen; V K Batish; Mandeep Saini
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 9.  Imaging evaluation of inflammation in the musculoskeletal system: current concepts and perspectives.

Authors:  Guillaume Bierry; Jean-Louis Dietemann
Journal:  Skeletal Radiol       Date:  2013-05-19       Impact factor: 2.199

Review 10.  The clinical application of radiopharmaceuticals.

Authors:  N E Leeds
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.